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Impact of Clinical Symptoms on Interpretation of Diagnostic Assays
for Clostridium difficile Infections䌤
Erik R. Dubberke,1* Zhuolin Han,1 Linda Bobo,1 Tiffany Hink,1 Brenda Lawrence,2 Susan Copper,2
Joan Hoppe-Bauer,2 Carey-Ann D. Burnham,3,4 and William Michael Dunne, Jr.1,3,4,5

Received 2 May 2011/Returned for modification 19 May 2011/Accepted 13 June 2011

Asymptomatic Clostridium difficile colonization is common in hospitalized patients. Existing C. difficile assay
comparisons lack data on severity of diarrhea or patient outcomes, limiting the ability to interpret their results
in regard to the diagnosis of C. difficile infection (CDI). The objective of this study was to measure how
including patient presentation with the C. difficile assay result impacted assay performance to diagnose CDI.
Stool specimens from 150 patients that met inclusion and exclusion criteria were selected. Nine methods to
detect C. difficile in stool were evaluated. All patients were interviewed prospectively to assess diarrhea severity.
We then assessed how different reference standards, with and without the inclusion of patient presentation,
impact the sensitivity, specificity, and positive and negative predictive values of the assays to diagnose CDI.
There were minimal changes in sensitivity; however, specificity was significantly lower for the assays Tox A/B
II, C. diff Chek-60, BD GeneOhm Cdiff, Xpert C. difficile, and Illumigene C. difficile and for toxigenic culture
(P was <0.01 for all except Tox A/B II from fresh stool, for which the P value was 0.016) when the reference
standard was recovery of toxigenic C. difficile from stool plus the presence of clinically significant diarrhea
compared to when the reference standard was having at least four assays positive while ignoring diarrhea
severity. There were 15 patients whose assay result was reported as negative but subsequently found to be
positive by at least four assays in the comparison. None suffered from any CDI-related adverse events. In
conclusion, clinical presentation is important when interpreting C. difficile diagnostic assays.
possible to determine the true meaning of a positive C. difficile
assay and how it relates to the diagnosis of CDI in the absence
of patient symptoms and outcomes (14).
In April 2009, the C. difficile toxin EIA used by our institution became unavailable due to manufacturing difficulties
(ProSpecT Clostridium difficile Toxin A/B; Remel, Lenexa,
KS). A significant drop in CDI incidence was noted when a
replacement toxin EIA was implemented (C. difficile Tox A/B
II; TechLab, Blacksburg, VA). An epidemiological study failed
to identify increased CDI related morbidity or mortality, suggesting the difference was due to improved specificity of the
new assay (7). To confirm this, and because of the limitations
of published studies, a formal assay comparison that included
prospective patient interviews and an assessment of outcomes
was conducted. These data were used to test the hypothesis
that the apparent specificity of any given C. difficile assay for
the diagnosis of CDI will decrease when clinical presentation
of the patient is included in the reference standard.
(These data were presented in part at the 21st Annual Meeting of the Society for Healthcare Epidemiology of America, 1
to 4 April 2011, Dallas, TX.)

Clostridium difficile infection (CDI) is the leading cause of
infectious nosocomial diarrhea in North America and Europe
(3). CDI incidence and severity have been increasing for the
last decade. These changes in CDI epidemiology have brought
renewed focus on methods to detect C. difficile and/or its toxins
in stool.
Because of the lower sensitivity to detect the presence of
toxigenic C. difficile in stool versus other methods, the Society
for Healthcare Epidemiology of America and Infectious Diseases Society of America CDI guidelines state that toxin enzyme immunoassays (EIAs) are a suboptimal approach for the
diagnosis of CDI (3). An alternative was not recommended,
leaving laboratory personnel to interpret the C. difficile diagnostic literature when choosing a substitute. Although the performance of C. difficile assays relative to each other can be
made, contemporary studies suffer from the use of different
reference standards and inconsistent reporting on the source
and consistency of specimens (23). More importantly, the current CDI diagnostic literature does not include prospective
patient interviews to assess clinical symptoms, medication exposures, and/or patient outcomes. CDI is a clinical diagnosis
supported by laboratory or endoscopic evidence, not vice
versa. The lack of clinical data is problematic, because asymptomatic C. difficile colonization and diarrhea are common in
populations exposed to health care facilities (3, 15, 16). It is not

MATERIALS AND METHODS
Patient population and stool specimen collection. The study was conducted at
Barnes-Jewish Hospital (BJH), in St. Louis, MO. The BJH microbiology laboratory only tests unformed stools for C. difficile, per published guidelines (3). C.
difficile testing requires an order from a physician for diagnostic purposes. Unformed stool, defined as stool that conforms to its container, submitted from
inpatients for C. difficile testing was eligible to be included in the comparison if
it was the first specimen sent during that admission and if a minimum of 10 ml
of stool was submitted. The specimen was tested and results reported per standard practice with the assay used by the clinical microbiology laboratory during
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TABLE 1. Reference standards for assay comparisonsa
Clinically
significant
diarrhea

Toxigenic
C. difficile
isolated

At least 4
assays
positive

Interpretation
for assay
comparison

A

Yes
No
Yes
No

Yes
Yes
No
No

NA
NA
NA
NA

Positive
Negative
Negative
Negative

B

Yes
No
Yes
No

Yes
Yes
No
No

NA
NA
NA
NA

Positive
Positive
Negative
Negative

C

Yes
No
Yes
No

NA
NA
NA
NA

Yes
Yes
No
No

Positive
Negative
Negative
Negative

D

Yes
No
Yes
No

NA
NA
NA
NA

Yes
Yes
No
No

Positive
Positive
Negative
Negative

Reference
standard

a
The presence of clinically significant diarrhea was ignored when interpreting
the reference standard and the assays being compared for standards B and D.
NA, not applicable.

C. difficile strains recovered from stool for which there was at least one positive
nucleic acid amplification assay result (13).
Statistical analysis. The a priori primary reference standard for the assay
evaluation was a patient with clinically significant diarrhea and toxigenic C.
difficile recovered from stool (standard A) (Table 1) (3). Three alternate reference standards were also evaluated to determine how different reference standards impact assay comparisons. These included (i) having the presence of
toxigenic C. difficile while ignoring clinical presentation (standard B), (ii) having
clinically significant diarrhea and at least four assays positive (standard C), and
(iii) having at least four assays positive while ignoring clinical presentation
(standard D). Only results from the frozen specimens were used for the “at least
four assays positive” criteria. Clinically significant diarrhea was defined as at least
three diarrheal bowel movements (type 6 or 7 stool on the Bristol Stool Chart)
in the 24 h preceding stool specimen collection or diarrhea plus patient-reported
abdominal pain or cramping (14). There were four C. difficile isolates that were
nontoxigenic but positive for the tcdB gene. These stool specimens were classified as negative for toxigenic C. difficile.
Sensitivity and specificity and their 95% confidence intervals were calculated
for each assay against each reference standard. The prevalence for positive and
negative predictive value calculations was based on the results of the respective
reference standard on the first 100 specimens alone. The impact of a two-step
algorithm, i.e., first screening specimens with a GDH EIA (C. diff Chek-60), was
also assessed. The algorithm was positive only if both the GDH and the second
assay were positive. The Wilcoxon rank sum test was used to compare continuous
and ordinal data. Chi-square and Fisher’s exact tests were used for categorical
data. Outcomes of patients whose clinical assay was reported as negative but was
positive by any of the reference standards were described. PASW v17.0 (IBM
SPSS, Inc., Somers, NY) and EpiInfo v6 (CDC, Atlanta, GA) were used for
statistical analysis.

RESULTS
The median age of the 150 patients who met inclusion and
exclusion criteria was 60 years (range, 21 to 96 years) (Table 2).
The race distribution was similar to that typical for BJH (4).
The median peak temperature within 24 h of stool collection
was 37.1°C (range, 35.6°C to 39.7°C), and 27 patients (18%)
had a fever of ⱖ38.3°C. Patients had significantly more bowel
movements per day compared to their baseline (median number of bowel movements was 3 versus 1 at baseline [P ⬍ 0.001])
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the study period (C. difficile Tox A/B II). The remaining specimen was divided
into 10 1-ml aliquots and frozen at ⫺80°C. Patients were interviewed within 24 h
of stool collection. Specimens were excluded if the patient was unable to communicate. The first 100 consecutive specimens that met inclusion and exclusion
criteria were included in the study. To better evaluate specificity, an additional 50
specimens that were positive using ProSpecT Clostridium difficile Toxin A/B, the
assay most frequently positive with the first 100 specimens, were collected. The
first 100 specimens were collected between 11 January 2010 and 5 February 2010,
and the last 50 specimens were collected between 19 March 2010 and 30 June
2010.
Patients were interviewed by one of two physicians with infectious diseases
training (E.R.D. or Z.H.). The first 10 interviews were conducted with both
physicians present to standardize the interview process and data collection. The
interviewers were blinded to the assay result reported to the treating physician.
Demographic data, select comorbidities (inflammatory bowel disease and intraabdominal surgery in the prior 7 days), and receipt of a laxative in the 48 h prior
to stool specimen collection were recorded. The patients were questioned on the
consistency and number of bowel movements in the 24 h prior to stool collection
and on what was typical for them. Patients selected stool consistency from the
Bristol Stool Chart. Patients rated abdominal pain or cramping on a scale from
1 (no pain/cramping) to 10 (most severe pain/cramping imaginable). An abdominal exam was performed, and the peak temperature and white blood cell count
within 24 h of stool collection were recorded. The outcome at 60 days (death or
recurrent CDI) and empirical CDI treatment for patients whose assay result was
reported as negative but found to be positive in the assay comparison were
assessed.
Testing of stool specimens. The assays compared included two toxin EIAs (C.
difficile Tox A/B II and ProSpecT Clostridium difficile Toxin A/B), one glutamate
dehydrogenase (GDH) EIA (C. diff Chek-60 [TechLab]), and three nucleic acid
amplification tests (BD GeneOhm Cdiff [Becton Dickinson, Franklin Lakes, NJ],
Xpert C. difficile [Cepheid, Sunnyvale, CA], and Illumigene C. difficile [Meridian
Bioscience, Inc., Cincinnati, OH]). All assays were performed according to the
manufacturers’ instructions (the C. difficile Tox A/B II and C. diff Chek-60
package inserts state that activity may be lost if the specimen is frozen, and the
Xpert C. difficile does not state whether specimens can be frozen prior to testing).
Although a positive result from the ProSpecT Clostridium difficile Toxin A/B
from fresh stool was part of the inclusion criteria for the final 50 specimens, the
results of this assay for the fresh specimen were not included in the comparison
because the assay was not performed on the first 100 specimens prior to freezing.
If the initial result of any assay was indeterminate, instructions provided by the
manufacturer to resolve the results of the assay were followed. If repeat results
remained indeterminate, the result recorded for the assay comparison was “negative.” The person performing the assays was blinded to the results of toxigenic
culture and to the clinical data.
The cytotoxicity cell assay was conducted for all stool specimens. Stool samples
were diluted 1:1 in phosphate-buffered saline to a total volume of 1 ml and
centrifuged for 10 min at 14,000 ⫻ g. The supernatant was filtered using a sterile
0.45 ⌴ low-protein-binding syringe filter. The cytotoxicity assay was performed
according to manufacturer’s directions (Clostridium difficile toxin/antitoxin kit;
TechLab). HT-29 adenocarcinoma intestinal cells (HTB 38; American Type
Culture Collection) grown to confluence in 96-well microtiter plates were used.
Samples were tested in duplicate. Cytoxicity was assessed after 24 and 48 h of
incubation in a 37°C CO2 incubator. Samples exhibiting typical cell rounding that
was neutralized with antitoxin were recorded as positive.
Toxigenic culture was performed for all specimens. Stool was incubated with
an equal amount of 95% ethanol (Sigma-Aldrich, St. Louis, MO) at room
temperature for 45 min. The specimen was centrifuged at 2,500 ⫻ g for 10 min,
and the supernatant was discarded. The pellet was inoculated onto prereduced
cycloserine, cefoxitin, and fructose agar with lysozyme (Anaerobe Systems, Morgan Hill, CA). Plates were inspected for growth after 48 h in an anaerobic
incubator at 35°C. Presumptive C. difficile isolates were identified, by characteristic colony morphology, smell, and Gram stain, that were also Pro Disk (Remel)
positive and spot indole (Remel) negative (6). All isolates were confirmed to be
C. difficile positive with RapID ANA II (Remel). Any specimen found to be
positive by at least two nonculture methods but not by C. difficile culture was
inoculated into prereduced cycloserine, cefoxitin, and mannitol broth with taurocholate and lysozyme (Anaerobe Systems) (22). If growth was identified within
a week of inoculation, the specimen was subcultured onto prereduced blood agar
(Remel). C. difficile isolates were identified as described above. All C. difficile
isolates were grown in chopped meat broth (Anaerobe Systems) for 48 h. Culture
was tested for cytotoxicity as described above. The presence of the tcdB gene was
assessed by PCR using the primers described by Peterson et al. in nontoxigenic
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C. DIFFICILE ASSAYS AND SYMPTOMS

TABLE 2. Demographic and clinical dataa
No. (%) or
median (range)

Patient characteristic

Age (yr).......................................................................... 60 (21–96)
Female............................................................................ 76 (50.7%)
Race
White.......................................................................... 105 (70.0%)
Black........................................................................... 43 (28.7%)
Other ..........................................................................
2 (1.4%)

a

13 (8.7%)
12 (8.0%)
28 (18.7%)
2.9 (0–42.3)
37.1 (35.6–39.7)
8.8 (0.1–70.0)
1 (⬍1–9)
3 (1–7)
3 (⬍1–20)
7 (3–7)
1 (1–10)
28 (18.7%)
53 (35.3%)
20 (13.3%)
20 (13.3%)
30 (20.0%)
96 (64%)

n ⫽ 150 patients. WBC, white blood cell; BSC, Bristol Stool Chart.

and were significantly more likely to have diarrhea compared
to their baseline (median Bristol Stool Chart score was 7 versus
3 at baseline [P ⬍ 0.001]). Ninety-six patients (64%) met criteria for clinically significant diarrhea. Twenty-eight patients
(19%) received a laxative in the 48 h prior to stool collection.
The results of the assay comparisons for standard A (i.e.,
positive toxigenic culture plus clinically significant diarrhea)
are presented in Table 3. The cytotoxicity cell assay was the
least sensitive (62.9%; 95% confidence interval [CI], 46.3% to

76.8%) in the comparison but was among the most specific
(93.9%; 95% CI, 88.0% to 97.0%). Of the two toxin EIAs in
the comparison, the Tox A/B from fresh stool was the least
sensitive assay (80.0%; 95% CI, 64.1% to 90.0%) and the
ProSpecT was the most sensitive (100%; 95% CI, 90.1% to
100%). Conversely, the most specific toxin EIA was the Tox
A/B from fresh stool (93.9%; 95% CI, 88.0% to 97.0%) and the
least specific was the ProSpecT (67.7%; 95% CI, 59.7% to
76.5%). All nucleic acid amplification tests, along with the
Chek-60 GDH EIA, demonstrated superior sensitivity, but
specificity was 86.1% or lower for these assays. A two-step
algorithm of an initial screen with the Chek-60 GDH EIA
resulted in a significant improvement in specificity for the
ProSpecT (P ⬍ 0.001).
The prevalence of CDI in the first 100 specimens by standard
A was 11%. The negative predictive value for all assays was
⬎95% (Table 3). The positive predictive values of ProSpecT,
Chek-60, and all three nucleic acid amplification tests were less
than 50%. A GDH screen decreased the number of false positives
for the nucleic acid amplification tests and ProSpecT, but the
positive predictive value increased to above 50% only for the
ProSpecT.
The results of the assay comparisons when the reference
standards were having positive toxigenic culture while ignoring
clinical presentation (standard B), having clinically significant
diarrhea and at least four assays positive (standard C), and
having at least four assays positive while ignoring clinical presentation (standard D) are provided in Tables 4, 5, and 6,
respectively. The relative rankings of the assays by sensitivity
and specificity within each comparison remain similar. The
sensitivity of toxigenic culture and the ProSpecT relative to
the other assays was lower when the laboratory component of
the reference standard was “at least four assays positive.”
The sensitivity of the assays was unchanged or decreased

TABLE 3. Assay comparison results with reference standard Aa

Assay

No. of
true-positive
results
(n ⫽ 35
specimens)

No. of
true-negative
results
(n ⫽ 115
specimens)

Sensitivity
(%) (95% CI)

Specificity
(%) (95% CI)

PPV
(%) (95% CI)

NPV
(%) (95% CI)

TechLab Tox A/B fresh
TechLab Tox A/B frozen
Remel ProSpecT frozen
Cytotoxicity from stool
TechLab Chek 60
BD GeneOhm
Cepheid
Illumigene
Toxigenic culture
GDH then TechLab Tox A/B frozen
GDH then Remel ProSpecT frozen
GDH then cytotoxicity from stool
GDH then BD GeneOhm
GDH then Cepheid
GDH then Illumigene
GDH then toxigenic culture

28
33
35
22
35
35
35
34
35
33
35
22
35
35
34
35

108
106
79
108
93
97
99
98
106
106
103
109
100
100
101
106

80.0 (64.1–90.0)
94.3 (81.4–98.4)
100 (90.1–100)
62.9 (46.3–76.8)
100 (90.1–100)
100 (90.1–100)
100 (90.1–100)
97.1 (85.5–99.5)
100 (90.1–100)
94.3 (81.4–98.4)
100 (90.1–100)
62.9 (46.3–76.8)
100 (90.1–100)
100 (90.1–100)
97.1 (85.5–99.5)
100 (90.1–100)

93.9 (88.0–97.0)
92.2 (85.8–95.8)
67.7 (59.7–76.5)
93.9 (88.0–97.0)
80.9 (72.7–87.0)
84.3 (76.6–89.9)
86.1 (78.6–91.3)
85.2 (77.6–90.6)
92.2 (85.8–95.8)
92.2 (85.8–95.8)
89.6 (82.6–93.9)
94.8 (89.1–97.6)
87.0 (79.6–91.9)
87.0 (79.6–91.9)
87.8 (80.1–92.6)
92.2 (85.8–95.8)

61.8 (39.8–78.8)
59.9 (41.5–74.3)
28.3 (21.7–34.5)
56.0 (32.3–76.0)
39.3 (29.0–48.7)
44.0 (32.2–55.0)
47.1 (34.2–58.7)
44.8 (32.1–56.7)
61.3 (44.0–74.6)
59.9 (41.5–74.3)
54.3 (39.0–67.0)
59.9 (34.4–79.8)
48.7 (35.5–60.4)
48.7 (35.3–60.4)
49.6 (34.7–62.4)
61.3 (44.0–74.6)

97.4 (95.2–98.7)
99.2 (97.4–99.8)
100 (98.0–100)
95.3 (93.0–97.1)
100 (98.3–100)
100 (98.4–100)
100 (98.5–100)
99.6 (97.7–99.9)
100 (98.6–100)
99.2 (97.4–99.8)
100 (98.5–100)
95.4 (93.1–97.1)
100 (98.5–100)
100 (98.5–100)
99.6 (97.8–99.9)
100 (98.6–100)

a
Shown are assay comparison results with reference standard A (stool samples positive by toxigenic culture plus the presence of clinically significant diarrhea). The
prevalence for positive predictive value (PPV) and negative predictive value (NPV) calculations was 11%. If samples were positive by a screen with glutamate
dehydrogenase EIA (GDH; TechLab Chek-60), the final result was positive only if the second assay was also positive. PPV and NPV estimates were calculated with
the CDI prevalence for the corresponding reference standard and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample; frozen, assay using
frozen stool sample.
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Inflammatory bowel disease ........................................
Abdominal surgery in previous 7 days.......................
Received laxative in previous 48 h.............................
Time from admission to stool collection (days) .......
Peak temp within 24 h of stool collection (°C) ........
Peak WBC count within 24 h of stool collection .....
Normal no. of bowel movements per day .................
Normal stool consistency (BSC type) ........................
Current no. of bowel movements per day.................
Current stool consistency (BSC type)........................
Abdominal pain or cramping ......................................
Hyper- or hypoactive bowel sounds ...........................
Abdominal tenderness .................................................
Abdominal distention...................................................
Involuntary guarding ....................................................
Rebound tenderness.....................................................
Clinically significant diarrhea......................................
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TABLE 4. Assay comparison results with reference standard Ba
No. of
true-negative
results
(n ⫽ 106
specimens)

Sensitivity
(%) (95% CI)

Specificity
(%) (95% CI)

PPV
(%) (95% CI)

NPV
(%) (95% CI)

TechLab Tox AB fresh
TechLab Tox AB frozen
Remel ProSpecT frozen
Cytotoxicity from stool
TechLab Chek 60
BD GeneOhm
Cepheid
Illumigene
Toxigenic culture
GDH then TechLab Tox AB frozen
GDH then Remel ProSpecT frozen
GDH then cytotoxicity from stool
GDH then BD GeneOhm
GDH then Cepheid
GDH then Illumigene
GDH then toxigenic culture

33
39
44
28
44
43
44
42
44
39
44
28
43
44
42
44

104
103
79
105
93
96
99
97
106
103
103
106
99
100
100
106

75.0 (60.6–85.4)
88.6 (76.0–95.1)
100 (92.0–100)
63.6 (48.9–76.2)
100 (92.0–100)
97.7 (88.2–99.6)
100 (92.0–100)
95.5 (84.9–98.7)
100 (92.0–100)
88.6 (76.0–95.1)
100 (92.0–100)
63.6 (48.9–76.2)
97.7 (88.2–99.6)
100 (92.0–100)
95.5 (84.9–98.7)
100 (92.0–100)

98.1 (93.4–99.5)
97.2 (92.0–99.0)
74.5 (65.5–81.9)
99.1 (94.9–99.8)
87.7 (80.1–92.7)
90.6 (83.5–94.8)
93.4 (87.0–96.8)
91.5 (84.7–95.5)
100 (96.5–100)
97.2 (92.0–99.0)
97.2 (92.0–99.0)
100 (96.5–100)
93.4 (87.0–96.8)
94.3 (88.2–97.4)
94.3 (88.2–97.4)
100 (96.5–100)

84.3 (55.6–95.9)
81.2 (56.2–92.8)
34.8 (26.7–43.0)
90.6 (56.7–98.1)
52.6 (38.7–65.1)
58.6 (42.2–72.3)
67.4 (49.1–81.0)
60.5 (43.1–74.9)
100 (78.2–100)
81.2 (56.4–92.8)
83.0 (61.1–93.2)
100 (65.6–100)
66.9 (48.1–80.9)
70.5 (51.5–84.0)
69.6 (49.5–83.8)
100 (78.2–100)

96.6 (94.6–98.0)
98.4 (96.6–99.3)
100 (98.4–100)
95.2 (93.2–96.9)
100 (98.7–100)
99.7 (98.1–99.9)
100 (98.8–100)
99.3 (97.6–99.8)
100 (98.9–100)
98.4 (96.6–99.3)
100 (98.8–100)
95.3 (93.3–96.9)
99.7 (98.2–99.9)
100 (98.9–100)
99.4 (97.7–99.8)
100 (98.9–100)

a
Shown are assay comparison results with reference standard B (stool samples positive by toxigenic culture only). The prevalence for positive predictive value (PPV)
and negative predictive value (NPV) calculations was 12%. If samples were positive by a screen with glutamate dehydrogenase EIA (GDH; TechLab Chek-60), the final
result was positive only if the second assay was also positive. PPV and NPV estimates were calculated with the CDI prevalence for the corresponding reference standard
and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample; frozen, assay using frozen stool sample.

with the alternate reference standards compared to standard
A. The only significant change was for toxigenic culture when
the reference standard was at having least four positive assays
while ignoring clinical presentation (standard D) (P ⫽ 0.04).
The specificity and positive predictive values of all of the assays
increased with standards B through D versus those for standard A. There were trends or significant increases in specificity
when standard B (having toxigenic culture while ignoring clinical presentation) was the reference standard for Tox A/B from
a frozen specimen, the cytotoxicity cell assay, Cepheid (0.1 ⱖ

P ⬎ 0.05 for all three), and toxigenic culture (P ⫽ 0.004).
When the reference standard was having at least four assays
positive while ignoring clinical presentation (standard D),
there were significant increases in specificity for Tox A/B from
fresh and frozen stool, Chek-60, BD GeneOhm, Cepheid, Illumigene, and toxigenic culture (P was ⬍0.01 for all except Tox
A/B from fresh stool, for which P was 0.016) compared that to
when standard A was the reference standard.
There were 15 patients whose stool specimen was reported
as negative for C. difficile toxins (Tox A/B from fresh stool) but

TABLE 5. Assay comparison results with reference standard Ca

Assay

No. of
true-positive
results
(n ⫽ 40
specimens)

No. of
true-negative
results
(n ⫽ 110
specimens)

Sensitivity
(%) (95% CI)

Specificity
(%) (95% CI)

PPV
(%) (95% CI)

NPV
(%) (95% CI)

TechLab Tox AB fresh
TechLab Tox AB frozen
Remel ProSpecT frozen
Cytotoxicity from stool
TechLab Chek 60
BD GeneOhm
Cepheid
Illumigene
Toxigenic culture
GDH then TechLab Tox AB frozen
GDH then Remel ProSpecT frozen
GDH then cytotoxicity from stool
GDH then BD GeneOhm
GDH then Cepheid
GDH then Illumigene
GDH then toxigenic culture

30
36
37
22
40
40
40
39
35
36
37
22
40
40
39
35

105
104
76
103
93
97
99
98
101
104
100
104
100
100
101
101

75.0 (59.8–85.8)
90.0 (77.0–96.0)
92.5 (80.1–97.4)
55.0 (39.8–69.3)
100 (91.2–100)
100 (91.2–100)
100 (91.2–100)
97.5 (87.1–99.6)
87.5 (73.9–94.5)
90.0 (77.0–96.0)
92.5 (80.1–97.4)
55.0 (39.8–69.3)
100 (91.2–100)
100 (91.2–100)
97.5 (87.1–99.6)
87.5 (73.9–94.5)

95.5 (89.8–98.0)
94.6 (88.6–97.5)
69.1 (59.9–77.0)
93.6 (87.4–96.9)
84.6 (76.6–90.1)
88.2 (80.8–93.0)
90.0 (83.0–94.3)
89.1 (81.9–93.7)
91.8 (85.2–95.6)
94.6 (88.6–97.5)
90.9 (84.1–95.0)
94.6 (88.6–97.5)
90.9 (84.1–95.0)
90.9 (84.1–95.0)
91.8 (85.2–95.6)
91.8 (85.2–95.6)

73.1 (48.8–87.5)
72.7 (52.4–86.2)
32.8 (24.5–40.8)
58.3 (34.0–78.4)
51.2 (38.8–62.2)
58.0 (43.6–69.9)
61.9 (46.6–74.1)
59.3 (43.9–72.0)
63.5 (44.8–77.8)
72.7 (52.4–86.2)
62.3 (45.1–76.0)
61.9 (36.2–81.9)
64.1 (48.3–76.5)
64.1 (48.3–76.5)
65.9 (48.9–78.7)
63.5 (44.8–77.8)

95.9 (93.2–97.7)
98.3 (95.9–99.3)
98.3 (94.9–99.5)
92.7 (89.9–95.1)
100 (98.2–100)
100 (98.3–100)
100 (98.3–100)
99.5 (97.5–99.9)
97.8 (95.2–99.1)
98.3 (95.9–99.3)
98.7 (96.3–99.6)
92.8 (90.0–95.1)
100 (98.3–100)
100 (98.3–100)
99.6 (97.6–99.9)
97.8 (95.2–99.1)

a
Shown are assay comparison results with reference standard C (stool samples positive by at least four assays from frozen specimens plus the presence of clinically
significant diarrhea). The prevalence for positive predictive value (PPV) and negative predictive value (NPV) calculations was 14%. If samples were positive by a screen
with glutamate dehydrogenase EIA (GDH; TechLab Chek-60), the final result was positive only if the second assay was also positive. PPV and NPV estimates were
calculated with the CDI prevalence for the corresponding reference standard and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample;
frozen, assay using frozen stool sample.
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TABLE 6. Assay comparison results with reference standard Da
No. of
true-negative
results
(n ⫽ 100
specimens)

Sensitivity
(%) (95% CI)

Specificity
(%) (95% CI)

PPV
(%) (95% CI)

NPV
(%) (95% CI)

TechLab Tox AB fresh
TechLab Tox AB frozen
Remel ProSpecT frozen
Cytotoxicity from stool
TechLab Chek 60
BD GeneOhm
Cepheid
Illumigene
Toxigenic culture
GDH then TechLab Tox AB frozen
GDH then Remel ProSpecT frozen
GDH then cytotoxicity from stool
GDH then BD GeneOhm
GDH then Cepheid
GDH then Illumigene
GDH then toxigenic culture

35
42
47
28
50
49
49
48
44
42
47
28
49
49
48
44

100
100
76
99
93
96
98
97
100
100
100
100
99
99
100
100

70.0 (56.3–80.1)
84.0 (71.5–91.7)
94.0 (83.8–97.9)
56.0 (42.3–68.8)
100 (92.9–100)
98.0 (89.5–99.7)
98.0 (89.5–99.7)
96.0 (86.5–98.9)
88.0 (76.2–94.4)
84.0 (71.5–91.7)
94.0 (83.8–97.9)
56.0 (42.3–68.8)
98.0 (89.5–99.7)
98.0 (89.5–99.7)
96.0 (86.5–98.9)
88.0 (76.2–94.4)

100 (96.3–100)
100 (96.3–100)
76.0 (66.8–83.3)
99.0 (94.6–99.8)
93.0 (86.3–96.6)
96.0 (90.2–98.4)
98.0 (93.0–99.5)
97.0 (91.6–99.0)
100 (96.3–100)
100 (96.3–100)
100 (96.3–100)
100 (96.3–100)
99.0 (94.6–99.8)
99.0 (94.6–99.8)
100 (96.3–100)
100 (96.3–100)

100 (74.3–100)
100 (78.6–100)
42.7 (32.5–52.8)
91.4 (59.9–98.5)
73.1 (56.4–84.9)
82.4 (63.5–92.2)
90.3 (70.9–97.4)
85.9 (66.2–95.0)
100 (79.7–100)
100 (78.6–100)
100 (81.2–100)
100 (68.5–100)
94.9 (75.9–99.0)
94.9 (75.9–99.0)
100 (81.7–100)
100 (79.7–100)

94.6 (92.0–96.3)
97.0 (94.7–98.4)
98.5 (95.6–99.5)
92.2 (89.6–94.4)
100 (98.5–100)
99.6 (97.8–99.9)
99.6 (97.9–99.9)
99.2 (97.3–99.8)
97.8 (95.5–98.9)
97.0 (94.7–98.4)
98.9 (96.9–99.6)
92.3 (89.9–94.4)
99.6 (97.9–99.9)
99.6 (97.9–99.9)
99.2 (97.4–99.8)
97.8 (95.5–98.9)

a
Shown are assay comparison results with reference standard D (stool samples positive by at least four assays only). The prevalence for positive predictive value
(PPV) and negative predictive value (NPV) calculations was 16%. If samples were positive by a screen with glutamate dehydrogenase EIA (GDH; TechLab Chek-60),
the final result was positive only if the second assay was also positive. PPV and NPV estimates were calculated with the CDI prevalence for the corresponding reference
standard and point estimates of sensitivity and specificity. Fresh, assay using fresh stool sample; frozen, assay using frozen stool sample.

was positive by at least four assays (Table 7). Eleven (73.3%)
of these patients were positive by toxigenic culture, and three
(20%) were positive by the cytotoxicity cell assay. Ten (66.7%)
had clinically significant diarrhea. Five (33.3%) of the patients
whose Tox A/B result from fresh stool was discordant with the
“at least four assays positive” criteria received a laxative in the
48 h prior to stool specimen collection compared to 23 patients
(17.0%) whose Tox A/B result from fresh stool was concordant
(P ⫽ 0.16). Four patients (26.7%) received empirical treat-

TABLE 7. Treatment and outcomes of patients whose C. difficile
test was reported as negative by Techlab Tox A/B from fresh
specimen but was positive by at least four assays
Subject
Clinically
Laxative
identification significant
use
no.
diarrhea

15a
21a
25
35b
54b
70b
82a,c
109a
112a
113a,c
118a,c
122a
126a
148a
149a
a

Yes
Yes
No
Yes
Yes
Yes
Yes
No
No
Yes
No
Yes
No
Yes
Yes

Yes
No
No
Yes
No
Yes
No
No
No
No
No
No
Yes
No
Yes

Empirical CDI
treatment

Died in
60-day
follow-up

Diagnosed
with CDI
in 60-day
follow-up

No
Metronidazole
No
No
No
No
Metronidazole
No
No
No
No
Vancomycin
Metronidazole
No
No

No
Yesd
No
No
Yese
No
No
No
No
No
No
No
No
No
Yesf

No
No
No
No
No
No
No
No
No
No
No
No
No
No
No

Toxigenic C. difficile isolated from stool.
Nontoxigenic C. difficile isolated from stool.
Cytotoxicity cell assay of stool was positive.
d
Patient died from ischemic cardiomyopathy.
e
Patient died from respiratory failure secondary to metastatic carcinoma.
f
Patient died from pneumonia.
b
c

ment for CDI. Three patients died from reasons unrelated to
CDI. None of the 15 patients were subsequently diagnosed
with CDI.
DISCUSSION
The C. difficile diagnostic assay literature suffers from use of
different reference standards, inconsistent reporting of stool
collection criteria, and most importantly, a lack of data on
severity of diarrhea and CDI-related outcomes. Asymptomatic
C. difficile colonization is common in patient populations that
are tested for C. difficile (3, 16). Therefore, data on the patient’s clinical presentation are needed for accurate interpretation of assay results for the diagnosis of CDI (3, 14). To our
knowledge, there is only one other C. difficile assay comparison
in the literature that included a prospective patient evaluation
of patients who had stools submitted for C. difficile testing
based on orders from a treating clinician (13). Peterson et al.
found the sensitivity, specificity, and positive and negative predictive values of their in-house nucleic acid amplification test
to be 93.3%, 97.4%, 75.7%, and 99.4%, respectively. Thirtynine percent of patients did not meet their criteria for clinically
significant diarrhea, similar to the 36% in this study. However,
they excluded the stools from these patients in their comparison. This likely biased the specificity of the assays in their
comparison to be higher than if these patients were not excluded. Therefore, our study, by including patients whose
treating clinicians ordered a test for C. difficile but who did not
have clinically significant diarrhea, is more generalizable to the
population of hospitalized patients being tested for C. difficile.
The results of this study support the hypothesis that including
clinical presentation in the reference standard will decrease
the specificity of C. difficile assays for the diagnosis of CDI.
Although limited by small sample size, the outcome data collected support this hypothesis, i.e., there were no CDI-related
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gator experienced in the technique (2). The performance of
the assay may be related to poor patient selection for C. difficile
testing. Conversely, the 95% confidence interval of the cytotoxicity cell assay overlaps with the 95% confidence intervals of
the Tox A/B and was within the ranges of reported sensitivities
in the literature (3, 22). It may have been the least sensitive
assay in this study by chance as well (22).
Some C. difficile assay comparisons use a nontoxigenic culture, noncytotoxicity cell assay reference standard, or composite endpoint where true positives are specimens that are positive by multiple assays (9, 11, 13, 18). Due to the difficulties of
performing toxigenic culture and the cytotoxicity cell assay, this
is frequently the reference standard that clinical laboratories
use when conducting assay comparisons and, hence, the reason
a composite laboratory standard was assessed here. There are
potential problems with this approach. The reference standard
is a surrogate for the desired endpoint (toxigenic C. difficile or
the presence of active toxin in stool). In addition, as demonstrated in this study, a composite endpoint biases the results
toward improved sensitivity and specificity of the assays included in the composite endpoint.
There were other interesting findings in this study. Although
the Techlab assays warn of a possible decrease in sensitivity
with freezing, the Tox A/B from the frozen specimen was more
sensitive than that from the fresh specimen, and the Chek-60
had 100% sensitivity. The Tox A/B from the frozen specimen
was performed by a single experienced medical technologist as
a part of this study. The Tox A/B from the fresh sample was
performed as part of a constellation of duties by a technologist
on the third shift. Other studies do indicate there may be
variability in toxin EIA sensitivities across laboratories (5, 12,
22). This may be due to operator variability. Notably, almost
20% of patients were on a laxative. This is indicative of poor
patient selection for C. difficile testing and may have impacted
our findings. The least specific assay was the ProSpecT. This
was consistent with the results of the epidemiological investigation that was performed when a dramatic drop in CDI incidence was noted after the assay at our institution was changed
to the Tox A/B (7).
This study demonstrates the importance of clinical information when interpreting C. difficile assay results. The high proportion of patients without clinically significant diarrhea and
the number of patients on laxatives indicate that we need
validated criteria for when to test for C. difficile. Another
potential area of study is validation of inflammatory biomarkers to help determine when detection of toxigenic C. difficile
from stool is clinically significant (1, 20). Finally, there is an
urgent need for C. difficile assay comparison studies that are
adequately powered to assess patient outcomes. Although
there has been great enthusiasm in the literature and the clinical microbiology community regarding the use of molecular
diagnostics for the diagnosis of CDI, the optimal method for
diagnosing CDI will remain elusive until these issues are resolved.
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adverse events in the patients whose assay result was reported
as negative (C. difficile Tox A/B II from fresh stool) but found
to be positive by other assays.
When clinical criteria were included in the reference standard, the positive predictive value of some assays decreased
such that there would be as many, if not more, false positives
as true positives (Tables 3 through 6). While it is important to
accurately diagnose true cases of CDI to avoid delays in treatment and the risk of disease progression, there are likely costs
due to false-positive results as well. In one placebo-controlled
study of treating asymptomatic C. difficile carriers, the only
patient to develop CDI after treatment was stopped had received oral vancomycin (8). Other potential costs include direct and indirect costs of placing patients under contact precautions when not otherwise indicated, decreases in patient
satisfaction, and increases in adverse events associated with
contact precautions (10, 17, 21). Increases in CDI incidence
due to false-positive assays will also divert limited infection
prevention and control resources and lead to false impressions
if CDI rates are reported to the public.
The appropriate reference standard when comparing C. difficile assays is not clear. The Society for Healthcare Epidemiology of America and Infectious Diseases Society of America
guidelines recommend toxigenic culture as the gold standard
laboratory comparator (B-III recommendation) (3). Toxigenic
C. difficile was not isolated from six specimens that were positive by at least four assays in this study. C. difficile was cultured
from five of these specimens, but cytotoxicity was not detected
from culture. These patients may have had more than one
strain of C. difficile present, and the isolates selected to assess
toxin production were nontoxigenic. Interestingly, four of these
strains were positive for the tcdB toxin B gene. The optimal
methods for detecting toxin production from culture have not
been defined (15, 19). It is possible that our method of performing the cytotoxicity cell assay was not sufficiently sensitive
to detect toxin production. Because of the discordance between cytotoxicity testing and the presence of the tcdB gene,
cytotoxicity testing of these isolates was repeated with Vero
cells, and the incubation period was extended to 96 h for both
cell lines. Cytotoxicity was still not identified. Two of these
patients had a negative Tox A/B result for fresh specimen and
were never treated for CDI (Table 7, subjects 35 and 70).
Subject 70 also had a colonoscopy, which was normal. The
other two patients had other potential explanations for diarrhea and had a very protracted improvement in symptoms after
CDI treatment was started, suggesting that the diarrhea was
not due solely to CDI. These unique strains are being further
characterized, by methods including whole-genome sequencing, to determine if the lack of cytotoxicity is due to a decrease
in toxin production or production of nonfunctional toxin.
Some investigators feel that toxigenic culture is too sensitive
and may detect asymptomatic carriage in patients with diarrhea for other reasons and that the cytotoxicity cell assay is the
most appropriate reference standard for identifying patients
with CDI because it detects biologically active toxin (15). Notably, the cytotoxicity cell assay was the least sensitive method
in this study. This may be due to degradation of toxin in the
specimen during transport or upon prolonged storage or methodological problems with the assay. However, the assay was
performed using methods previously described by an investi-
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